Coverage
-
April 30, 2014
The Third Circuit on Wednesday upheld a lower court ruling that generic manufacturers of equivalents of the bone drug Fosamax could not be held liable for injuries supposedly incurred by drug users, concluding that the state-law claims asserted in the suit were preempted by federal law.
2 other articles on this case.
View all »